These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21054679)

  • 1. Innovator and generic cisplatin formulations: comparison of renal toxicity.
    Sekine I; Kubota K; Tamura Y; Asahina H; Yamada K; Horinouchi H; Nokihara H; Yamamoto N; Tamura T
    Cancer Sci; 2011 Jan; 102(1):162-5. PubMed ID: 21054679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis.
    Niho S; Yamanaka T; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2013 Apr; 43(4):390-5. PubMed ID: 23444114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy.
    Oike T; Ohno T; Noda SE; Sato H; Tamaki T; Kiyohara H; Ando K; Nakano T
    J Radiat Res; 2013 May; 54(3):474-8. PubMed ID: 23242248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the Safety of a Generic Formulation of Cisplatin in Patients with Thoracic Malignancies].
    Ueda Y; Kondo Y; Suzuki H; Okamoto N; Morishita N; Tamiya M; Shiroyama T; Kumode A; Usui N; Nakano H; Sando M; Tanaka E; Hirashima T
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):827-32. PubMed ID: 26197744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
    Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.
    Riva N; Guido PC; Ibañez J; Licciardone N; Rousseau M; Mato G; Monteverde M; Schaiquevich P
    Int J Clin Pharm; 2014 Aug; 36(4):779-86. PubMed ID: 24861769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.
    Ochi N; Yamane H; Hotta K; Fujii H; Isozaki H; Honda Y; Yamagishi T; Kubo T; Tanimoto M; Kiura K; Takigawa N
    Drug Des Devel Ther; 2014; 8():2401-8. PubMed ID: 25584019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma.
    Lad DP; Malhotra P; Patil AN; Nampoothiri RV; Kasudhan KS; Khadwal A; Prakash G; Jain A; Malhotra S; Varma N; Attri SV; Varma S
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):114-118. PubMed ID: 32622756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
    Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
    Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the protective effect of Cystone against cisplatin-induced nephrotoxicity in cancer patients, and its influence on cisplatin antitumor activity.
    El-Ghiaty MA; Ibrahim OM; Abdou SM; Hussein FZ
    Int Urol Nephrol; 2014 Jul; 46(7):1367-73. PubMed ID: 24448757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
    Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
    J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
    Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
    Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing real-life carbamazepine exposure between innovator and generic formulation.
    Gaïes E; Jebabli N; Zerei S; Charfi R; Salouage I; Ben Sassi M; El Jebari H; Daghfous R; Trabelsi S
    Therapie; 2022; 77(5):523-526. PubMed ID: 35184882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity Evaluation on Cisplatin Combined with 5-HT
    Kou W; Qin H; Hanif S; Wu X
    Biomed Res Int; 2018; 2018():1024324. PubMed ID: 29977907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
    Prasaja Y; Sutandyo N; Andrajati R
    Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.